Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.
Media Info
Our media releases, presentations for the media and useful links
2024
April 23, 2024
Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances
Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, whereas privately financed companies were able to increase both R&D investments and liquidity reserves – Record number of product approvals by Swissmedic, EMA and FDA – including world’s first CRISPR gene editing therapy – Swiss Biotech Day increases international presence with full launch of Global Village, the partnering platform for international delegations
Media releases & presentations 2024
Download PDF of media releaseDownload media presentation Record revenues of CHF 7.3…
Download PDF of media release Download media presentation in English Rekordumsatz von…
Download PDF of media release Download media presentation in English Recettes record…
The Swiss Biotech Report media presentation 2023 is only available in English Download PDF
2023
April 25, 2023
Swiss Biotech Report 2023 shows sector weathers global disruption well and continues to play a leading role driving global healthcare innovation
Record revenues of CHF 6.8 billion (USD 7.5 billion) – Fund raising of CHF 1.3 billion (USD 1.5 billion) exceeding pre-COVID 19 levels of 2019: CHF 0.78 billion by public companies, CHF 0.55 billion by private companies – 47 new approvals by Swissmedic – R&D investment again increased to a record level of CHF 2.7 billion (USD 3.0 billion) – Ecosystem continues to strengthen and attract – 20% of European biotech companies now headquartered in Switzerland – Employment continues to rise to new record level – FTE’s in Swiss R&D biotech companies increased in 2022 by 7.2% – Swiss Biotech Association celebrates highlights of 25 years of Swiss biotech R&D achievements
Media releases & presentations 2023
Download PDF of media releaseDownload media presentation Record revenues of CHF 6.8…
Download PDF of media releaseDownload media presentation in English Rekordumsatz von…
Download PDF of media releaseDownload media presentation in English Recettes record de…
The Swiss Biotech Report media presentation 2023 is only available in English Download PDF
2022
December 12, 2022
Investment advisor Chandra P. Leo joins Swiss Biotech Success Stories’ jury
Since 2018, the Swiss Biotech Association has been honoring outstanding achievements with the Swiss Biotech Success Stories Awards. Once a year, innovative companies, entrepreneurs and scientists are recognized by the industry association for their significant successes and lasting contributions to the Swiss biotech industry. Chandra P. Leo has now joined the Swiss Biotech Success Stories’ jury. The next Swiss Biotech Success Story Awards will be announced at the Swiss Biotech Day in Basel on April 24 – 25, 2023.
May 3, 2022
Swiss Biotech Report 2022 shows sector again performs exceptionally at all levels
Capital investments in Swiss biotech companies reached CHF 3.33B (USD 3.53B) with continuing strong international participation – R&D investments increased to a record-high CHF 2.56B (USD 2.71B) – The appetite for IPOs on the NASDAQ remains high and the new Sparks market of SIX Swiss Exchange for SMEs could offer an interesting alternative in the future – The number of employees in Swiss R&D biotech companies increased in 2021 by 9.5% – Public-Private Partnerships (PPPs) increasing in importance as drivers of innovation in existing and emerging areas – Similar to 2020, significant contributions to address the impact of the COVID pandemic were made by the Swiss biotech sector in 2021
February 14, 2022
Swiss Biotech Association welcomes referendum result on February 13, 2022
The industry association of the Swiss biotech start-ups and SMEs welcomes that the Swiss electorate has rejected the proposal to ban animal testing and clinical trials. This enables Switzerland to continue to play its leading international role in the development of innovative medicines and new medical therapies. Moreover, the Swiss healthcare system retains access to innovative medicines from abroad. With one of the strictest animal protection laws in the world, Switzerland also ensures that animal tests are carried out with the utmost care and will be replaced by alternative methods wherever possible.
January 17, 2022
Radical people’s initiative bans clinical trials and risks to severely damage the Swiss research hub and healthcare system
The Swiss Biotech Association emphasizes the serious consequences of the radical people’s initiative
«Yes to the ban on animal testing and clinical trials», which will be put to the vote on February 13, 2022. In addition to banning clinical trials in Switzerland, the initiative also calls for a ban on the import of new medicines developed using clinical trials. The adoption of this initiative would have a massive impact on the Swiss healthcare system and directly threatens Switzerland as a research location. Research-oriented companies and their academic research partners in universities and university hospitals would have to stop their research work or relocate significant parts of their research and development activities abroad.
Media releases & presentations 2022
Download PDF of media release Since 2018, the Swiss Biotech Association has been…
Download PDF of media release Seit 2018 zeichnet die Swiss Biotech Association…
Download PDF of media release Depuis 2018, la Swiss Biotech Association met à…
Download PDF of media release Download media presentation Capital investments in Swiss…
Download PDF of media releaseDownload media presentation in English 2021 wurden 3,33…
Download PDF of media releaseDownload media presentation in English En 2021, CHF 3,33…
The Swiss Biotech Report media presentation 2022 is only available in English Download PDF
Download PDF The industry association of the Swiss biotech start-ups and SMEs…
Download PDF Der Branchenverband der schweizerischen Biotech Startups und KMUs…
Download PDF L’association des start-up et PME suisses de biotechnologie salue…
Download PDF The Swiss Biotech Association emphasizes the serious consequences of the…
Download PDF Die Swiss Biotech Association warnt eindringlich vor den gravierenden…
Download PDF La Swiss Biotech Association souligne les graves conséquences de…
2021
September 7, 2021
Swiss Biotech Day: Switzerland is extraordinarily successful as a biotech hub and globally connected
Switzerland is one of the most attractive locations for biotech companies and benefits from a very high influx of venture capital. At the same time, Switzerland has excellent prerequisites for further expanding its strong position in manufacturing complex biopharmaceuticals, as illustrated by numerous reports, presentations and panel discussions at the leading Swiss biotech industry conference.
May 12, 2021
Weakening patent protection for COVID-19 vaccines does not help to accelerate vaccine production but endangers science-based innovation
The proposal to the WTO, to weaken the patent protection for COVID-19 vaccines, incorrectly portrays IP as the barrier to rapid access to vaccines. While this initiative does not address the crisis in an effective manner, it does send an extremely dangerous signal to innovators and investors alike. A robust and reliable IP protection is indispensable for science-based innovation. What sounds good at first glance is dangerous as it risks to significantly weaken our ability to foster and finance healthcare innovation.
April 20, 2021
Agility, leadership and innovation – New Swiss Biotech Report shows exceptional sector performance
Capital investments in Swiss biotech companies almost tripled from 2019 to 2020 reaching CHF 3.4B (USD 3.7B) – R&D investments increased by 10% to CHF 2.2B (USD 2.3B) – The number of employees in Swiss R&D biotech companies increased by 8% to 16,300 – High quality patent output helped maintain Switzerland’s top ranking in Global Innovation Index for the tenth consecutive year – From rapid diagnostic test and vaccine manufacturing to drug repurposing, Swiss biotech companies made significant contributions to address the impact of the COVID-19 pandemic
The Swiss Biotech Report “Aglity, leadership and innovation in the time of COVID-19” launched by the Swiss Biotech Association in conjunction with EY and eight other partner organizations provides analysis of funding, M&A activity and collaborations. The report also highlights projects and companies that were part of the Swiss response to the COVID-19 pandemic.
March 31, 2021
Swiss Biotech Association now at headquarters of the Basel Chamber of Commerce
The Swiss Biotech Association will open a representative office at the Basel Chamber of Commerce on April 1, 2021. This demonstrates its commitment to Basel as a life sciences location with its innovative companies. Together with the Basel Chamber of Commerce, they are committed to a strong, competitive life sciences industry in the Basel region and Switzerland.
February 26, 2021
Swiss Biotech Success Stories with new jury members
Since 2018, the Swiss Biotech Association has been honoring outstanding achievements with the Swiss Biotech Success Stories Awards. Innovative companies, entrepreneurs and scientists are recognized by the industry association for their significant successes and lasting contributions to the Swiss biotech industry. Stefanie Flückiger-Mangual, Seraina Gross and Daniela Marino have now joined the Swiss Biotech Success Stories jury.Media releases & presentations 2021
Download PDF Switzerland is one of the most attractive locations for biotech companies…
Download PDF Die Schweiz gehört zu den attraktivsten Standorten für…
Download PDF La Suisse figure parmi les sites les plus attrayants pour les entreprises…
The Swiss Biotech Report media presentation 2021 is only available in English Download PDF
Download PDF The proposal to the WTO, to weaken the patent protection for COVID-19…
Download PDF Im Vorschlag an die WTO, den Patentschutz für COVID-19-Impfstoffe…
Download PDF La proposition faite à l’OMC de réduire la protection offerte par les…
Download PDF Capital investments in Swiss biotech companies almost tripled from 2019…
Download PDF Ob in der Entwicklung von Schnelldiagnosetests, neuer Therapiemethoden…
Download PDF Qu’il s’agisse de développement de tests de diagnostic rapide, de…
The Swiss Biotech Report media presentation 2021 is only available in English Download PDF
Download PDF The Swiss Biotech Association will open a representative office at the…
Download PDF Die Swiss Biotech Association eröffnet am 1. April 2021 eine Repräsentanz…
Download PDF Since 2018, the Swiss Biotech Association has been honoring outstanding…
Download PDF Seit 2018 zeichnet die Swiss Biotech Association hervorragende Leistungen…
Download PDF Depuis 2018, la Swiss Biotech Association distingue les performances…
